{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:31:03Z","timestamp":1789036263544,"version":"build-2803163510"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"16","license":[{"start":{"date-parts":[[2022,1,9]],"date-time":"2022-01-09T00:00:00Z","timestamp":1641686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P20 GM119943 (O.D.L. and P.J.Q.), P20 GM103652 (O.D.L.), R01 HL141268 (C.E.V.), and T32 HL116249 (E.-Y.S., O.D.L., and P.J.Q.)"],"award-info":[{"award-number":["P20 GM119943 (O.D.L. and P.J.Q.), P20 GM103652 (O.D.L.), R01 HL141268 (C.E.V.), and T32 HL116249 (E.-Y.S., O.D.L., and P.J.Q.)"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"American Heart Association Transformational Project Award","award":["18TPA34110329 (O.D.L.)"],"award-info":[{"award-number":["18TPA34110329 (O.D.L.)"]}]},{"name":"Rhode Island Foundation Medical Research Fund","award":["Nr. 5219_20200595 (E.-M.J. and O.D.L.)"],"award-info":[{"award-number":["Nr. 5219_20200595 (E.-M.J. and O.D.L.)"]}]},{"name":"Academic Assessment Research Award from the Brown Physicians, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Pulmonary arterial hypertension (PAH) is a fatal disease without a cure. Previously, we found that transcription factor RUNX1-dependent haematopoietic transformation of endothelial progenitor cells may contribute to the pathogenesis of PAH. However, the therapeutic potential of RUNX1 inhibition to reverse established PAH remains unknown. In the current study, we aimed to determine whether RUNX1 inhibition was sufficient to reverse Sugen\/hypoxia (SuHx)-induced pulmonary hypertension (PH) in rats. We also aimed to demonstrate possible mechanisms involved.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>We administered a small molecule specific RUNX1 inhibitor Ro5-3335 before, during, and after the development of SuHx-PH in rats to investigate its therapeutic potential. We quantified lung macrophage recruitment and activation in vivo and in vitro in the presence or absence of the RUNX1 inhibitor. We generated conditional VE-cadherin-CreERT2; ZsGreen mice for labelling adult endothelium and lineage tracing in the SuHx-PH model. We also generated conditional Cdh5-CreERT2; Runx1(flox\/flox) mice to delete Runx1 gene in adult endothelium and LysM-Cre; Runx1(flox\/flox) mice to delete Runx1 gene in cells of myeloid lineage, and then subjected these mice to SuHx-PH induction. RUNX1 inhibition in vivo effectively prevented the development, blocked the progression, and reversed established SuHx-induced PH in rats. RUNX1 inhibition significantly dampened lung macrophage recruitment and activation. Furthermore, lineage tracing with the inducible VE-cadherin-CreERT2; ZsGreen mice demonstrated that a RUNX1-dependent endothelial to haematopoietic transformation occurred during the development of SuHx-PH. Finally, tissue-specific deletion of Runx1 gene either in adult endothelium or in cells of myeloid lineage prevented the mice from developing SuHx-PH, suggesting that RUNX1 is required for the development of PH.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>By blocking RUNX1-dependent endothelial to haematopoietic transformation and pulmonary macrophage recruitment and activation, targeting RUNX1 may be as a novel treatment modality for pulmonary arterial hypertension.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cvr\/cvac001","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T20:10:04Z","timestamp":1641499804000},"page":"3211-3224","source":"Crossref","is-referenced-by-count":45,"title":["Targeting RUNX1 as a novel treatment modality for pulmonary arterial hypertension"],"prefix":"10.1093","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1620-7837","authenticated-orcid":false,"given":"Euy-Myoung","family":"Jeong","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Rhode Island Hospital, Warren Alpert Medical School of Brown University , Providence, RI 02903 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3999-9048","authenticated-orcid":false,"given":"Mandy","family":"Pereira","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Rhode Island Hospital, Warren Alpert Medical School of Brown University , Providence, RI 02903 , USA"},{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Rhode Island Hospital, Warren Alpert Medical School of Brown University , Providence, RI 02903 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eui-Young","family":"So","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Rhode Island Hospital, Warren Alpert Medical School of Brown University , Providence, RI 02903 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith Q","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Rhode Island Hospital, Warren Alpert Medical School of Brown University , Providence, RI 02903 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5229-0359","authenticated-orcid":false,"given":"Michael","family":"Del Tatto","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Rhode Island Hospital, Warren Alpert Medical School of Brown University , Providence, RI 02903 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4428-3634","authenticated-orcid":false,"given":"Sicheng","family":"Wen","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Rhode Island Hospital, Warren Alpert Medical School of Brown University , Providence, RI 02903 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0653-6562","authenticated-orcid":false,"given":"Mark S","family":"Dooner","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Rhode Island Hospital, Warren Alpert Medical School of Brown University , Providence, RI 02903 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja M","family":"Dubielecka","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Rhode Island Hospital, Warren Alpert Medical School of Brown University , Providence, RI 02903 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M","family":"Reginato","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Rhode Island Hospital, Warren Alpert Medical School of Brown University , Providence, RI 02903 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey E","family":"Ventetuolo","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Rhode Island Hospital, Warren Alpert Medical School of Brown University , Providence, RI 02903 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J","family":"Quesenberry","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Rhode Island Hospital, Warren Alpert Medical School of Brown University , Providence, RI 02903 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R","family":"Klinger","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Rhode Island Hospital, Warren Alpert Medical School of Brown University , Providence, RI 02903 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2266-6722","authenticated-orcid":false,"given":"Olin D","family":"Liang","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Rhode Island Hospital, Warren Alpert Medical School of Brown University , Providence, RI 02903 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,9]]},"reference":[{"key":"2022122915243445000_cvac001-B1","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra035488","article-title":"Pulmonary arterial hypertension","volume":"351","author":"Farber","year":"2004","journal-title":"N Engl J Med"},{"key":"2022122915243445000_cvac001-B2","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1016\/j.jacc.2004.02.037","article-title":"Clinical classification of pulmonary hypertension","volume":"43","author":"Simonneau","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2022122915243445000_cvac001-B3","doi-asserted-by":"crossref","first-page":"D34","DOI":"10.1016\/j.jacc.2013.10.029","article-title":"Updated clinical classification of pulmonary hypertension","volume":"62","author":"Simonneau","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2022122915243445000_cvac001-B4","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/j.jacc.2015.03.540","article-title":"Management of pulmonary arterial hypertension","volume":"65","author":"McLaughlin","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2022122915243445000_cvac001-B5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pcad.2012.07.002","article-title":"WHO Group 1 pulmonary arterial hypertension: current and investigative therapies","volume":"55","author":"Ventetuolo","year":"2012","journal-title":"Prog Cardiovasc Dis"},{"key":"2022122915243445000_cvac001-B6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1161\/CIRCRESAHA.113.301141","article-title":"Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension","volume":"115","author":"Rabinovitch","year":"2014","journal-title":"Circ Res"},{"key":"2022122915243445000_cvac001-B7","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1164\/rccm.201608-1630PP","article-title":"The roles of immunity in the prevention and evolution of pulmonary arterial hypertension","volume":"195","author":"Nicolls","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2022122915243445000_cvac001-B8","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1387\/ijdb.103106gs","article-title":"Hematopoietic stem cell emergence in the conceptus and the role of Runx1","volume":"54","author":"Swiers","year":"2010","journal-title":"Int J Dev Biol"},{"key":"2022122915243445000_cvac001-B9","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1038\/emboj.2012.275","article-title":"RUNX1 reshapes the epigenetic landscape at the onset of haematopoiesis","volume":"31","author":"Lichtinger","year":"2012","journal-title":"EMBO J"},{"key":"2022122915243445000_cvac001-B10","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nature07619","article-title":"Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter","volume":"457","author":"Chen","year":"2009","journal-title":"Nature"},{"key":"2022122915243445000_cvac001-B11","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1038\/sj.onc.1207670","article-title":"Structure and regulated expression of mammalian RUNX genes","volume":"23","author":"Levanon","year":"2004","journal-title":"Oncogene"},{"key":"2022122915243445000_cvac001-B12","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1073\/pnas.93.8.3444","article-title":"Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis","volume":"93","author":"Wang","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022122915243445000_cvac001-B13","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/cvr\/cvx161","article-title":"Endothelial to haematopoietic transition contributes to pulmonary arterial hypertension","volume":"113","author":"Liang","year":"2017","journal-title":"Cardiovasc Res"},{"key":"2022122915243445000_cvac001-B14","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1615\/CritRevImmunol.v32.i6.10","article-title":"M1 and M2 macrophages: oracles of health and disease","volume":"32","author":"Mills","year":"2012","journal-title":"Crit Rev Immunol"},{"key":"2022122915243445000_cvac001-B15","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1016\/j.ajpath.2017.05.014","article-title":"M1 macrophage-induced endothelial-to-mesenchymal transition promotes infantile hemangioma regression","volume":"187","author":"Wu","year":"2017","journal-title":"Am J Pathol"},{"key":"2022122915243445000_cvac001-B16","doi-asserted-by":"crossref","first-page":"22011","DOI":"10.1074\/jbc.M116.715953","article-title":"Runt-related transcription factor 1 (RUNX1) binds to p50 in macrophages and enhances TLR4-triggered inflammation and septic shock","volume":"291","author":"Luo","year":"2016","journal-title":"J Biol Chem"},{"key":"2022122915243445000_cvac001-B17","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/ATVBAHA.113.301453","article-title":"Transcriptional control of macrophage polarization","volume":"33","author":"Tugal","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022122915243445000_cvac001-B18","doi-asserted-by":"crossref","first-page":"14592","DOI":"10.1073\/pnas.1200037109","article-title":"Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFbeta interaction","volume":"109","author":"Cunningham","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022122915243445000_cvac001-B19","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1165\/rcmb.2019-0154OC","article-title":"Mesenchymal stem cell extracellular vesicles reverse Sugen\/hypoxia pulmonary hypertension in rats","volume":"62","author":"Klinger","year":"2020","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2022122915243445000_cvac001-B20","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.stem.2008.09.018","article-title":"Fate tracing reveals the endothelial origin of hematopoietic stem cells","volume":"3","author":"Zovein","year":"2008","journal-title":"Cell Stem Cell"},{"key":"2022122915243445000_cvac001-B21","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1002\/dvdy.20982","article-title":"VE-cadherin-CreERT2 transgenic mouse: a model for inducible recombination in the endothelium","volume":"235","author":"Monvoisin","year":"2006","journal-title":"Dev Dyn"},{"key":"2022122915243445000_cvac001-B22","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nature09002","article-title":"Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis","volume":"465","author":"Wang","year":"2010","journal-title":"Nature"},{"key":"2022122915243445000_cvac001-B23","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/nprot.2008.71","article-title":"Isolation of endothelial cells from fresh tissues","volume":"3","author":"van Beijnum","year":"2008","journal-title":"Nat Protoc"},{"key":"2022122915243445000_cvac001-B24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1023\/A:1008942828960","article-title":"Conditional gene targeting in macrophages and granulocytes using LysMcre mice","volume":"8","author":"Clausen","year":"1999","journal-title":"Transgenic Res"},{"key":"2022122915243445000_cvac001-B25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jim.2014.05.009","article-title":"Comparative analysis of the efficiency and specificity of myeloid-Cre deleting strains using ROSA-EYFP reporter mice","volume":"408","author":"Abram","year":"2014","journal-title":"J Immunol Methods"},{"key":"2022122915243445000_cvac001-B26","first-page":"140","article-title":"Rat macrophage lysosomal membrane antigen recognized by monoclonal antibody ED1","volume":"83","author":"Damoiseaux","year":"1994","journal-title":"Immunology"},{"key":"2022122915243445000_cvac001-B27","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.3389\/fimmu.2019.02275","article-title":"Editorial: alveolar macrophages in lung inflammation and resolution","volume":"10","author":"Hu","year":"2019","journal-title":"Front Immunol"},{"key":"2022122915243445000_cvac001-B28","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.pcad.2012.07.006","article-title":"Immune and inflammatory mechanisms in pulmonary arterial hypertension","volume":"55","author":"El Chami","year":"2012","journal-title":"Prog Cardiovasc Dis"},{"key":"2022122915243445000_cvac001-B29","first-page":"275","article-title":"Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension","volume":"144","author":"Tuder","year":"1994","journal-title":"Am J Pathol"},{"key":"2022122915243445000_cvac001-B30","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1161\/CIRCULATIONAHA.106.655837","article-title":"Diverse contribution of bone marrow-derived cells to vascular remodeling associated with pulmonary arterial hypertension and arterial neointimal formation","volume":"115","author":"Sahara","year":"2007","journal-title":"Circulation"},{"key":"2022122915243445000_cvac001-B31","doi-asserted-by":"crossref","first-page":"L238","DOI":"10.1152\/ajplung.90591.2008","article-title":"Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment","volume":"297","author":"Burke","year":"2009","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2022122915243445000_cvac001-B32","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1161\/CIRCULATIONAHA.110.978627","article-title":"Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension","volume":"123","author":"Vergadi","year":"2011","journal-title":"Circulation"},{"key":"2022122915243445000_cvac001-B33","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1164\/rccm.201202-0335OC","article-title":"Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension","volume":"186","author":"Savai","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2022122915243445000_cvac001-B34","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.4049\/jimmunol.1701287","article-title":"Inflammatory macrophage expansion in pulmonary hypertension depends upon mobilization of blood-borne monocytes","volume":"200","author":"Florentin","year":"2018","journal-title":"J Immunol"},{"key":"2022122915243445000_cvac001-B35","doi-asserted-by":"crossref","first-page":"200ra117","DOI":"10.1126\/scitranslmed.3006674","article-title":"Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension","volume":"5","author":"Tian","year":"2013","journal-title":"Sci Transl Med"},{"key":"2022122915243445000_cvac001-B36","doi-asserted-by":"crossref","first-page":"2045894019882635","DOI":"10.1177\/2045894019882635","article-title":"A new treatment for severe pulmonary arterial hypertension based on an old idea: inhibition of 5-lipoxygenase","volume":"10","author":"Voelkel","year":"2020","journal-title":"Pulm Circ"},{"key":"2022122915243445000_cvac001-B37","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.201809-1631LE","article-title":"IL-1 blockade reduces inflammation in pulmonary arterial hypertension and right ventricular failure: a single-arm, open-label, phase IB\/II pilot study","volume":"199","author":"Trankle","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2022122915243445000_cvac001-B38","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1182\/blood-2011-12-353466","article-title":"Hemogenic endothelium during development and beyond","volume":"119","author":"Hirschi","year":"2012","journal-title":"Blood"},{"key":"2022122915243445000_cvac001-B39","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/dvdy.20643","article-title":"VE-Cadherin-Cre-recombinase transgenic mouse: a tool for lineage analysis and gene deletion in endothelial cells","volume":"235","author":"Alva","year":"2006","journal-title":"Dev Dyn"},{"key":"2022122915243445000_cvac001-B40","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1182\/blood-2002-05-1511","article-title":"Identification of the hemangioblast in postnatal life","volume":"100","author":"Pelosi","year":"2002","journal-title":"Blood"},{"key":"2022122915243445000_cvac001-B41","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1634\/stemcells.2006-0783","article-title":"Hemogenic endothelial progenitor cells isolated from human umbilical cord blood","volume":"25","author":"Wu","year":"2007","journal-title":"Stem Cells"},{"key":"2022122915243445000_cvac001-B42","doi-asserted-by":"crossref","first-page":"e51109","DOI":"10.1371\/journal.pone.0051109","article-title":"Human haemato-endothelial precursors: cord blood CD34+ cells produce haemogenic endothelium","volume":"7","author":"Pelosi","year":"2012","journal-title":"PLoS One"},{"key":"2022122915243445000_cvac001-B43","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/s41467-018-03672-4","article-title":"Identification of rare sequence variation underlying heritable pulmonary arterial hypertension","volume":"9","author":"Graf","year":"2018","journal-title":"Nat Commun"},{"key":"2022122915243445000_cvac001-B44","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1164\/rccm.201804-0766LE","article-title":"SOX17 mutations in Japanese patients with pulmonary arterial hypertension","volume":"198","author":"Hiraide","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2022122915243445000_cvac001-B45","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13073-018-0566-x","article-title":"Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital heart disease","volume":"10","author":"Zhu","year":"2018","journal-title":"Genome Med"},{"key":"2022122915243445000_cvac001-B46","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S2213-2600(18)30409-0","article-title":"Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis","volume":"7","author":"Rhodes","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2022122915243445000_cvac001-B47","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13073-021-00891-1","article-title":"Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH","volume":"13","author":"Zhu","year":"2021","journal-title":"Genome Med"},{"key":"2022122915243445000_cvac001-B48","doi-asserted-by":"crossref","first-page":"7739","DOI":"10.1038\/ncomms8739","article-title":"Repression of arterial genes in hemogenic endothelium is sufficient for haematopoietic fate acquisition","volume":"6","author":"Lizama","year":"2015","journal-title":"Nat Commun"},{"key":"2022122915243445000_cvac001-B49","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1242\/dev.121350","article-title":"Single-cell resolution of morphological changes in hemogenic endothelium","volume":"142","author":"Bos","year":"2015","journal-title":"Development"},{"key":"2022122915243445000_cvac001-B50","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1161\/CIRCULATIONAHA.116.025722","article-title":"SOX17 regulates conversion of human fibroblasts into endothelial cells and erythroblasts by dedifferentiation into CD34(+) progenitor cells","volume":"135","author":"Zhang","year":"2017","journal-title":"Circulation"},{"key":"2022122915243445000_cvac001-B51","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1182\/blood-2012-05-431403","article-title":"Role of SOX17 in hematopoietic development from human embryonic stem cells","volume":"121","author":"Nakajima-Takagi","year":"2013","journal-title":"Blood"},{"key":"2022122915243445000_cvac001-B52","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/cvr\/cvaa034","article-title":"RUNX1: an emerging therapeutic target for cardiovascular disease","volume":"116","author":"Riddell","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2022122915243445000_cvac001-B53","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1161\/CIRCULATIONAHA.117.028911","article-title":"Runx1 deficiency protects against adverse cardiac remodeling after myocardial infarction","volume":"137","author":"McCarroll","year":"2018","journal-title":"Circulation"},{"key":"2022122915243445000_cvac001-B54","doi-asserted-by":"crossref","first-page":"e013112","DOI":"10.1161\/JAHA.119.013112","article-title":"MicroRNA-101 protects against cardiac remodeling following myocardial infarction via downregulation of runt-related transcription factor 1","volume":"8","author":"Li","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2022122915243445000_cvac001-B55","doi-asserted-by":"crossref","first-page":"dev186569","DOI":"10.1242\/dev.186569","article-title":"Runx1 promotes scar deposition and inhibits myocardial proliferation and survival during zebrafish heart regeneration","volume":"147","author":"Koth","year":"2020","journal-title":"Development"},{"key":"2022122915243445000_cvac001-B56","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3390\/molecules23061479","article-title":"Targeting transcription factors for cancer treatment","volume":"23","author":"Lambert","year":"2018","journal-title":"Molecules"},{"key":"2022122915243445000_cvac001-B57","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1093\/infdis\/172.5.1246","article-title":"A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection","volume":"172","author":"Haubrich","year":"1995","journal-title":"J Infect Dis"},{"key":"2022122915243445000_cvac001-B58","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0166-3542(95)00980-9","article-title":"2-Glycineamide-5-chlorophenyl 2-pyrryl ketone, a non-benzodiazepin Tat antagonist, is effective against acute and chronic HIV-1 infections in vitro","volume":"32","author":"Kira","year":"1996","journal-title":"Antiviral Res"},{"key":"2022122915243445000_cvac001-B59","doi-asserted-by":"crossref","first-page":"6802","DOI":"10.1128\/jvi.66.11.6802-6805.1992","article-title":"Restoration of cell surface CD4 expression in human immunodeficiency virus type 1-infected cells by treatment with a Tat antagonist","volume":"66","author":"Shahabuddin","year":"1992","journal-title":"J Virol"},{"key":"2022122915243445000_cvac001-B60","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.2337\/db16-1035","article-title":"Identification of RUNX1 as a mediator of aberrant retinal angiogenesis","volume":"66","author":"Lam","year":"2017","journal-title":"Diabetes"},{"key":"2022122915243445000_cvac001-B61","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1158\/1541-7786.MCR-18-0922","article-title":"HDAC1 is a required cofactor of CBFbeta-SMMHC and a potential therapeutic target in inversion 16 acute myeloid leukemia","volume":"17","author":"Richter","year":"2019","journal-title":"Mol Cancer Res"},{"key":"2022122915243445000_cvac001-B62","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ebiom.2016.04.032","article-title":"Small molecule inhibitor of CBFbeta-RUNX binding for RUNX transcription factor driven cancers","volume":"8","author":"Illendula","year":"2016","journal-title":"EBioMedicine"},{"key":"2022122915243445000_cvac001-B63","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.aaa0314","article-title":"Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFbeta-SMMHC delays leukemia in mice","volume":"347","author":"Illendula","year":"2015","journal-title":"Science"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cardiovascres\/advance-article-pdf\/doi\/10.1093\/cvr\/cvac001\/42248030\/cvac001.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/118\/16\/3211\/48443850\/cvac001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/118\/16\/3211\/48443850\/cvac001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T15:26:21Z","timestamp":1672327581000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/118\/16\/3211\/6501427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,9]]},"references-count":63,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2022,1,9]]},"published-print":{"date-parts":[[2022,12,29]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvac001","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,1,9]]}}}